Skip to main content

Clinical Trials Using Melphalan

Review the clinical trials studying melphalan on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 50

Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Status: Active
Location: Yale University, New Haven, Connecticut
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Status: Active
Location: Yale University, New Haven, Connecticut
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Bendamustine with or without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
CYT107 for the Treatment of Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
TCR Alpha/Beta-Depleted Progenitor Cells with CD45RA-Depleted Donor Lymphocyte Infusion and Selected Use of Blinatumomab in Children and Young Adults with Blood Cancers at High Risk for Relapse
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Orca-T following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody with Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Adding Hyperbaric Oxygen Therapy to Allogeneic Stem Cell Transplant for Treating Hematologic Cancers
Status: Active
Location: University of Rochester, Rochester, New York
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Status: Active
Location: 310 locations